EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder

Aleksi Hamina, Heidi Taipale, Johannes Lieslehto, Markku Lähteenvuo, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Jari Tiihonen

JAMA Network Open · 09.10.2024 · 7 (10) · e2438358

DOI: 10.1001/jamanetworkopen.2024.38358 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 09.10.2024. Verfasst von Aleksi Hamina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia, Olanzapine, Comparative Effectiveness Research. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Antipsychotics are the cornerstone of maintenance treatment in schizophrenia spectrum disorders, but it is unclear which agents should be prioritized by prescribers.

Objective

To investigate the clinical effectiveness of antipsychotics, including recent market entries, in comparison with oral olanzapine in relapse and treatment failure prevention among individuals with schizophrenia spectrum disorder. Design, Setting, and Participants This comparative effectiveness research study with a within-individual analysis included data from Swedish health care registers of inpatient and specialized outpatient care, sickness absence, and disability pensions among all individuals aged 16 to 65 years who were diagnosed with schizophrenia spectrum disorder from January 1, 2006, to December 31, 2021, including an incident cohort and a prevalent cohort. Exposures Specific antipsychotics. Main Outcomes and Measures The risks for psychosis relapse hospitalization and treatment failure (psychiatric hospitalization, death, or change in an antipsychotic medication) were adjusted for the temporal order of treatments, time since cohort entry, and concomitant drugs. Comparisons of all antipsychotics with oral olanzapine, the most commonly used antipsychotic, were investigated.

Results

Among the full cohort of 131 476 individuals, the mean (SD) age of the study cohort was 45.7 (16.2) years (70 054 men [53.3%]). During a median follow-up of 12.0 years [IQR, 5.2-16.0 years], 48.5% of patients (N = 63 730) experienced relapse and 71.1% (N = 93 464) underwent treatment failure at least once. Compared with oral olanzapine, paliperidone 3-month long-acting injectable (LAI) was associated with the lowest adjusted hazard ratio (AHR) in the prevention of relapses (AHR, 0.66; 95% CI, 0.51-0.86), followed by aripiprazole LAI (AHR, 0.77 [95% CI, 0.70-0.84]), olanzapine LAI (AHR, 0.79 [95% CI, 0.73-0.86]), and clozapine (AHR, 0.82 [95% CI, 0.79-0.86]). Quetiapine was associated with the highest risk of relapse (AHR, 1.44 [95% CI, 1.38-1.51]). For prevention of treatment failure, paliperidone 3-month LAI was associated with the lowest AHR (AHR, 0.36 [95% CI, 0.31-0.42]), followed by aripiprazole LAI (AHR, 0.60 [95% CI, 0.57-0.63]), olanzapine LAI (AHR, 0.67 [95% CI, 0.63-0.72]), and paliperidone 1-month LAI (AHR, 0.71 [95% CI, 0.68-0.74]). Conclusions and Relevance This comparative effectiveness research study demonstrated large differences in the risk of relapse and treatment failure among specific antipsychotic treatments. The findings contradict the widely held conception that all antipsychotics are equally effective in relapse prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsSchizophreniaOlanzapineComparative Effectiveness ResearchHumansMaleFemaleMiddle AgedAdultSwedenAdolescentYoung AdultAgedTreatment OutcomeCohort StudiesHospitalizationRecurrenceClozapine

Substanzen

Antipsychotic AgentsOlanzapineClozapine

Autor:innen und Institutionen

  • Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Norwegian Centre for Addiction Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Zitieren

APA

Hamina, A., Taipale, H., Lieslehto, J., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2024). Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder. JAMA Network Open, 7(10), e2438358. https://doi.org/10.1001/jamanetworkopen.2024.38358

Vancouver

Hamina A, Taipale H, Lieslehto J, Lähteenvuo M, Tanskanen A, Mittendorfer-Rutz E, et al. Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder. JAMA Network Open. 2024;7(10):e2438358. doi:10.1001/jamanetworkopen.2024.38358

BibTeX
@article{Hamina2024,
  author = {Hamina, Aleksi and Taipale, Heidi and Lieslehto, Johannes and Lähteenvuo, Markku and Tanskanen, Antti and Mittendorfer-Rutz, Ellenor and Tiihonen, Jari},
  title = {Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {10},
  pages = {e2438358},
  doi = {10.1001/jamanetworkopen.2024.38358}
}
Kostenlos starten →